The following is a summary of “Biological characterization and clinical significance of cuproptosis-related genes in lung ...
News Medical on MSN3d
Ultrasensitive ctDNA detection improves risk prediction in early-stage lung cancerUltrasensitive ctDNA detection with NeXT Personal shows 81% sensitivity in early-stage lung adenocarcinoma, improving ...
Pancreatic Cancer Action Network Calls for Urgently Needed Research and Funding for Effective Early Detection Strategy and ...
GlobalData on MSN1d
CDE grants BTD to Innovent’s IBI343 for pancreatic cancerThe Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted breakthrough ...
GlobalData on MSN2d
German PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trialThe Paul-Ehrlich-Institute (PEI) in Germany has granted approval to continue subject enrolment in cohort 5 of Oncolytics ...
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for lung cancer announced today that the first ...
Tigilanol tiglate is under clinical development by QBiotics Group and currently in Phase I for Adenocarcinoma.
Pharmacogenomics. 2014;15(11):1507-1518. MEK/CDK4 PD-0325901 (MEKi) + palbociclib (CDK4i) NCT02022982 MEK/CDK4 Trametinib (MEKi) + palbociclib (CDK4i) NCT02065063 ...
BERGEN, Norway, Jan. 7, 2025 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for lung ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback